These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 15589466)

  • 1. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease.
    Sarmiento E; Fernàndez-Yáñez J; Muñoz P; Palomo J; Rodríguez-Molina JJ; Bermejo J; Catalan P; Bouza E; Fernández-Cruz E; Carbone J
    Int Immunopharmacol; 2005 Jan; 5(1):97-101. PubMed ID: 15589466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?
    Corales R; Chua J; Mawhorter S; Young JB; Starling R; Tomford JW; McCarthy P; Braun WE; Smedira N; Hobbs R; Haas G; Pelegrin D; Majercik M; Hoercher K; Cook D; Avery RK
    Transpl Infect Dis; 2000 Sep; 2(3):133-9. PubMed ID: 11429024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of cytomegalovirus disease after heart transplantation: persistence of anti-cytomegalovirus IgM antibodies.
    Iberer F; Halwachs-Baumann G; Rödl S; Pleisnitzer A; Wasler A; Auer T; Petutschnigg B; Müller H; Tscheliessnigg K; Wilders-Truschnig M
    J Heart Lung Transplant; 1994; 13(3):405-11. PubMed ID: 8061015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
    Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy.
    Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Prenner G
    Scand J Infect Dis Suppl; 1995; 99():100-3. PubMed ID: 8668929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
    Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
    Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.
    Sarmiento E; Diez P; Arraya M; Jaramillo M; Calahorra L; Fernandez-Yañez J; Palomo J; Sousa I; Hortal J; Barrio J; Alonso R; Muñoz P; Navarro J; Vicario J; Fernandez-Cruz E; Carbone J
    Transpl Infect Dis; 2016 Dec; 18(6):832-843. PubMed ID: 27639067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin induction therapy in renal transplant recipients: Effects on immunoglobulin and regulatory antibody levels.
    Staak A; Renner F; Suesal C; Dietrich H; Rainer L; Kamali-Ernst S; Ernst W; Padberg W; Opelz G; Weimer R
    Transplant Proc; 2006 Dec; 38(10):3483-5. PubMed ID: 17175311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections.
    Carbone J; Sarmiento E; Palomo J; Fernandez-Yañez J; Muñoz P; Bouza E; Rodríguez-Molina J; Lanio N; Fernandez-Cruz E
    Transplant Proc; 2007 Sep; 39(7):2385-8. PubMed ID: 17889198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
    Sarmiento E; Lanio N; Gallego A; Rodriguez-Molina J; Navarro J; Fernandez-Yañez J; Palomo J; Rodríguez-Hernández C; Ruiz M; Alonso R; Fernandez-Cruz E; Carbone J
    Int Immunopharmacol; 2009 Jun; 9(6):649-52. PubMed ID: 18940269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes.
    Yamani MH; Avery R; Mawhorter S; Young JB; McNeill A; Cook DJ; Ratiff NB; McCarthy P; Starling RC
    Transpl Infect Dis; 2001; 3 Suppl 2():40-3. PubMed ID: 11926749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS; Romano G; Mastroianni C; Roberta C; Della Corte A; Amarelli C; Maiello C; Giannolo B; Marra C; Ragone E; Grimaldi M; Utili R; Scardone M; Cotrufo M
    Transplant Proc; 2005; 37(6):2684-7. PubMed ID: 16182784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections.
    Carbone J; Sarmiento E; Del Pozo N; Rodriguez-Molina JJ; Navarro J; Fernandez-Yañez J; Palomo J; Villa A; Muñoz P; Fernandez-Cruz E
    Clin Transplant; 2012; 26(3):E277-83. PubMed ID: 22686951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
    Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.
    Schulz U; Solidoro P; Müller V; Szabo A; Gottlieb J; Wilkens H; Enseleit F
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S5-10. PubMed ID: 26900992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mycophenolate mofetil in heart transplantation.
    Mathieu P; Carrier M; White M; Pellerin M; Perrault L; Pelletier G; Robitaille D; Pelletier LC
    Can J Surg; 2000 Jun; 43(3):202-6. PubMed ID: 10851414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definitions of cytomegalovirus disease after heart transplantation: antigenemia as a marker for antiviral therapy.
    Iberer F; Tscheliessnigg K; Halwachs G; Rehak P; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Freigassner M; Prenner G; Hipmair G; Grasser B
    Transpl Int; 1996; 9(3):236-42. PubMed ID: 8723193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients.
    Kocher AA; Bonaros N; Dunkler D; Ehrlich M; Schlechta B; Zweytick B; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2003 Mar; 22(3):250-7. PubMed ID: 12633691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.